KPRX KIORA PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, KIORA PHARMACEUTICALS INC reported revenue of n/a, net income of −$2.08M and diluted EPS of −$0.34; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.
KPRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$12.8M, net income −$10.8K (margin n/a), EPS −$2.64
- Fiscal year ended Dec 2024: revenue $16.0M, gross profit n/a, operating income $4.51M, net income $3.60K (margin 0.0%), EPS $0.87
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$12.6M, net income −$12.5K (margin n/a), EPS −$24.25
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$12.3M, net income −$13.6M (margin n/a), EPS −$18.55
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$14.2M, net income −$13.8M (margin n/a), EPS −$57.12
KPRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.08M, EPS −$0.34
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.42M, EPS −$0.58
- Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income $4.31M, EPS −$1.59
- Quarter ended Sep 30, 2025: revenue $0, net income $26.8K, EPS $0.01
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$2.15M, EPS −$0.54
- Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$2.19M, EPS −$0.52
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$7.81M, EPS −$1.25
- Quarter ended Sep 30, 2024: revenue $0, net income −$3.41M, EPS −$0.81
- Quarter ended Jun 30, 2024: revenue $20.0K, net income −$2.22M, EPS −$0.53
- Quarter ended Mar 31, 2024: revenue $16.0M, net income $13.5M, EPS $3.46
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income $10.2M, EPS −$8.80
- Quarter ended Sep 30, 2023: revenue $0, net income −$5.76M, EPS −$7.30
- Quarter ended Jun 30, 2023: revenue $0, net income −$2.61M, EPS −$7.15
- Quarter ended Mar 31, 2023: revenue $0, net income −$1.87M, EPS −$1.00
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$2.50M, EPS −$1.07
- Quarter ended Sep 30, 2022: revenue n/a, net income −$5.12M, EPS −$6.03
- Quarter ended Jun 30, 2022: revenue n/a, net income −$2.40M, EPS −$0.18
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.57M, EPS −$11.27
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$6.18M, EPS −$45.17
- Quarter ended Sep 30, 2021: revenue n/a, net income −$3.03M, EPS −$11.34
KPRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$9.96M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $8.56M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$9.56M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$10.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$10.7M, share buybacks n/a
KPRX balance sheet
- Jun 30, 2026: cash $7.08M, total assets $23.8M, total liabilities $6.92M, shareholders' equity $16.9M
- Mar 31, 2026: cash $11.0M, total assets $21.2M, total liabilities $7.29M, shareholders' equity $13.9M
- Dec 31, 2025: cash $8.70M, total assets $24.3M, total liabilities $8.13M, shareholders' equity $16.1M
- Sep 30, 2025: cash $5.51M, total assets $29.9M, total liabilities $7.45M, shareholders' equity $22.4M
- Jun 30, 2025: cash $1.03M, total assets $31.9M, total liabilities $9.82M, shareholders' equity $22.1M
- Mar 31, 2025: cash $3.77M, total assets $34.0M, total liabilities $10.3M, shareholders' equity $23.7M
- Dec 31, 2024: cash $3.79M, total assets $36.5M, total liabilities $10.7M, shareholders' equity $25.8M
- Sep 30, 2024: cash $5.64M, total assets $38.5M, total liabilities $8.48M, shareholders' equity $30.0M
What is KPRX's revenue?
KIORA PHARMACEUTICALS INC reported $0 of revenue for the fiscal year ended December 2025.
Is KPRX profitable?
No. KIORA PHARMACEUTICALS INC lost $162K over the last four quarters.
What is KPRX's EPS?
Diluted earnings per share over the last four quarters were −$2.50; −$0.34 in the latest quarter.